Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.phrs.2022.106201
Title: | COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt? | Authors: | Ho, Wei Shen Zhang, Ruirui Tan, Yeong Lan Chai, Christina Li Lin |
Keywords: | Science & Technology Life Sciences & Biomedicine Pharmacology & Pharmacy Antivirals COVID-19 Small molecule therapeutics Drug discovery Chloroquine (PubChem CID 2719) Ivermectin (PubChem CID 6321424) Lopinavir (PubChem CID 92727) Ritonavir (PubChem CID 392622) Remdesivir (PubChem CID 121304016) Dexamethasone (PubChem CID 5743) Baricitinib (PubChem CID 44205240) Molnupiravir (Pubchem CID 145996610) Nirmatrelvir (PubChem CID 155903259) Chemical compounds studied in this article Hydroxychloroquine (PubChem CID 3652) ACUTE RESPIRATORY SYNDROME IN-VITRO LOPINAVIR-RITONAVIR EBOLA-VIRUS IVERMECTIN INHIBITORS CHLOROQUINE EFFICACY REMDESIVIR DRUG |
Issue Date: | 1-May-2022 | Publisher: | ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD | Citation: | Ho, Wei Shen, Zhang, Ruirui, Tan, Yeong Lan, Chai, Christina Li Lin (2022-05-01). COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?. PHARMACOLOGICAL RESEARCH 179. ScholarBank@NUS Repository. https://doi.org/10.1016/j.phrs.2022.106201 | Abstract: | The coronavirus disease 2019 (COVID-19) pandemic had grounded the world to a standstill. As the disease continues to rage two years on, it is apparent that effective therapeutics are critical for a successful endemic living with COVID-19. A dearth in suitable antivirals has prompted researchers and healthcare professionals to investigate existing and developmental drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although some of these drugs initially appeared to be promising for the treatment of COVID-19, they were ultimately found to be ineffective. In this review, we provide a retrospective analysis on the merits and limitations of some of these drugs that were tested against SARS-CoV-2 as well as those used for adjuvant therapy. While many of these drugs are no longer part of our arsenal for the treatment of COVID-19, important lessons can be learnt. The recent inclusion of molnupiravir and Paxlovid™ as treatment options for COVID-19 represent our best hope to date for endemic living with COVID-19. Our viewpoints on these two drugs and their prospects as current and future antiviral agents will also be provided. | Source Title: | PHARMACOLOGICAL RESEARCH | URI: | https://scholarbank.nus.edu.sg/handle/10635/226977 | ISSN: | 10436618 10961186 |
DOI: | 10.1016/j.phrs.2022.106201 |
Appears in Collections: | Elements Staff Publications |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
COVID-19 and the promise of small molecule therapeutics Are there lessons to be learnt.pdf | Published version | 4.33 MB | Adobe PDF | CLOSED | None |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.